DE60137525D1 - Peg-modifiziertes erythropoietin - Google Patents

Peg-modifiziertes erythropoietin

Info

Publication number
DE60137525D1
DE60137525D1 DE60137525T DE60137525T DE60137525D1 DE 60137525 D1 DE60137525 D1 DE 60137525D1 DE 60137525 T DE60137525 T DE 60137525T DE 60137525 T DE60137525 T DE 60137525T DE 60137525 D1 DE60137525 D1 DE 60137525D1
Authority
DE
Germany
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137525T
Other languages
English (en)
Inventor
Teruo Nakamura
Yasuo Sekimori
Minoru Machida
Hiromitsu Kawata
Hajime Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60137525D1 publication Critical patent/DE60137525D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
DE60137525T 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin Expired - Lifetime DE60137525D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000315421 2000-10-16
PCT/JP2001/008539 WO2002032957A1 (fr) 2000-10-16 2001-09-28 Erythropoietine modifiee par peg

Publications (1)

Publication Number Publication Date
DE60137525D1 true DE60137525D1 (de) 2009-03-12

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137525T Expired - Lifetime DE60137525D1 (de) 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (de)
EP (1) EP1333036B1 (de)
JP (1) JP5170931B2 (de)
AT (1) ATE421535T1 (de)
AU (1) AU2001290312A1 (de)
DE (1) DE60137525D1 (de)
ES (1) ES2320101T3 (de)
WO (1) WO2002032957A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MXPA05006994A (es) 2002-12-27 2005-10-18 Diobex Inc Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
EP1471153A3 (de) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transkriptionsaktivitätsassay
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
JP2007537986A (ja) * 2003-05-30 2007-12-27 セントカー・インコーポレーテツド トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
CA2549011A1 (en) * 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
EP1699915B1 (de) * 2003-12-30 2010-06-02 Augustinus Bader Verwendung des erythropoietins zur regeneration von lebergewebe
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
EP2380435B1 (de) 2005-08-31 2016-05-25 Kaneka Corporation Von Katzen stammendes Erythropoietin und Herstellungsverfahren dafür
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US10300144B2 (en) * 2006-07-25 2019-05-28 Lipoxen Technologies Limited N-terminal polysialylation
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
US8765924B2 (en) * 2006-08-04 2014-07-01 Prolong Pharmaceuticals, Inc. Modified erythropoietin
EP2101821B1 (de) 2006-12-15 2014-08-13 Baxter International Inc. Faktor-viia-(poly)sialsäurekonjugat mit verlängerter in-vivo-halbwertszeit
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
KR101486449B1 (ko) 2008-01-11 2015-01-26 세리나 쎄라퓨틱스, 인코포레이티드 다작용성 형태의 폴리옥시졸린 공중합체 및 이를 포함하는 약물 조성물
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
EP2837392A3 (de) * 2009-09-15 2015-05-13 Kaneka Corporation Modifiziertes Erythropoietin, dem ein wasserlösliches langkettiges Molekül hinzugefügt wird
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (ja) 1988-01-19 1996-05-29 松下電器産業株式会社 バ―ナ
JPH029900A (ja) * 1988-04-12 1990-01-12 Kirin Amgen Inc 修飾エリスロポエチン
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NO934477L (no) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG hydrazon- og PEG oksim-bindingdannende reagenser og proteinderivater derav
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69631329T2 (de) * 1995-03-10 2004-11-18 Sumitomo Pharmaceuticals Co., Ltd. Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
PT964702E (pt) * 1996-08-02 2006-12-29 Ortho Mcneil Pharm Inc Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
AU2346900A (en) * 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2204509T3 (es) 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag Conjugados de gcsf.
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives

Also Published As

Publication number Publication date
ATE421535T1 (de) 2009-02-15
AU2001290312A1 (en) 2002-04-29
JPWO2002032957A1 (ja) 2004-02-26
EP1333036A4 (de) 2004-09-29
WO2002032957A1 (fr) 2002-04-25
US20060276634A1 (en) 2006-12-07
US8022191B2 (en) 2011-09-20
ES2320101T3 (es) 2009-05-19
JP5170931B2 (ja) 2013-03-27
EP1333036B1 (de) 2009-01-21
EP1333036A1 (de) 2003-08-06
US20040082765A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
DE60137525D1 (de) Peg-modifiziertes erythropoietin
ATE252601T1 (de) Lang wirkende insulinotrope peptide
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
CY1113347T1 (el) Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα
IS3824A (is) Protein með bundið polyethylen og aðferð til framleiðslu þess
ATE364654T1 (de) Polyamideketten von genauer länge und deren konjugate mit proteinen
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
DE3786000T2 (de) Conjugate dichter sterne.
EA200400067A1 (ru) Конъюгаты гксф
CO5190661A1 (es) Derivados de la eritropoyetina
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DK1274728T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
ATE505204T1 (de) Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
DE68906366T2 (de) CD4-Polypeptidderivate.
DE69432141T2 (de) Taxane mit furyl-oder thienyl substituierten seitenketten
ATE471956T1 (de) Verzweigte polyalkylenglykole
DK0557199T3 (da) Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser
TR200200599T2 (tr) İnsan insülini monomerik analogları.
WO2004014951A3 (en) Binding molecules
ATE313796T1 (de) Konjugate definierter stöchiometrie
CY1115962T1 (el) Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα
RU2001102084A (ru) Настольная игра
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
YU29492A (sh) Konjugati proteina sa polietilenom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition